WASHINGTON, July 15 (Reuters) – Pete Hegseth, the U.S. Secretary of Defense, has ordered mandatory testosterone deficiency screening for all active-duty and reserve service members over age 30. The policy, first reported by The Guardian and confirmed by CBS News, takes effect immediately. Hegseth calls it a necessary intervention against a “silent epidemic” undermining combat readiness. Critics argue it risks over-medicalization and ignores systemic burnout.
The mandate requires annual blood tests for every soldier over 30. Hegseth asserts that low testosterone impairs cognitive function, physical performance, and morale. “This is about lethality,” he told Pentagon officials. “We cannot afford a force running on empty.” Follow-up treatments, including testosterone replacement therapy (TRT), will be offered. Privacy concerns linger over how flagged medical records might affect deployment and promotion.
The military currently struggles with mental health, traumatic brain injury, and opioid abuse. Hegseth’s move targets a neglected biological factor. Data suggests stress, sleep deprivation, and toxic exposures—such as burn pits and PFAS—drive hormone decline in uniform. Veterans and active-duty personnel have linked low T to depression, higher injury rates, and premature discharge. The Defense Department has not released prevalence figures for the over-30 cohort.
Supporters see the mandate as proactive. Conservative hawks praise Hegseth for prioritizing warrior health. Progressive lawmakers question the cost and equity of universal screening. Endocrinologists note that while TRT can improve symptoms, over-prescription carries cardiovascular risks. The policy echoes past military health mandates—such as anthrax vaccination and PTSD screening—which sparked controversy over consent and efficacy.
Internationally, no major NATO ally—including the UK, Israel, or Australia—routinely screens soldiers for testosterone deficiency. Hegseth’s policy is unprecedented in scale. Military families face secondary impacts: improved soldier health could reduce household stress, but mandatory testing may stigmatize hormone therapy and male infertility within ranks. The cultural shift normalizes hormonal health checks, yet critics warn it could mask deeper issues like burnout and PTSD.
Implementation remains unclear. Screening protocols, lab capacity, and treatment pipelines must be built. Hegseth insists the program will be paired with comprehensive wellness initiatives. “Soldiers over 30 deserve better,” he said. The debate is whether this mandate delivers that promise or creates new problems. Success hinges on execution and trust.
💡 Frequently Asked Questions (FAQ)
- Q: What is Hegseth’s testosterone screening mandate?
- A: U.S. Defense Secretary Pete Hegseth has ordered mandatory testosterone deficiency screening for all active-duty and reserve service members over age 30, requiring annual blood tests to identify low testosterone levels.
- Q: Why is the mandate controversial?
- A: Critics argue it risks over-medicalization, privacy breaches affecting deployment and promotion, and ignores systemic issues like mental health, burnout, and toxic exposures that may drive hormone decline.
- Q: What conditions does Hegseth say the mandate addresses?
- A: Hegseth asserts low testosterone impairs cognitive function, physical performance, and morale, calling it a ‘silent epidemic’ that undermines combat readiness and lethality.
- Q: What treatments are offered under the policy?
- A: Follow-up treatments, including testosterone replacement therapy (TRT), will be offered to service members flagged with deficiency.
Extended Reading
The Guardian reported Hegseth’s announcement on July 15, 2026. CBS News confirmed the annual screening requirement. The Hill noted the policy’s political divide, with conservative lawmakers backing Hegseth and progressives demanding cost-benefit analysis. No official Pentagon data on testosterone deficiency prevalence among service members over 30 has been released.